Explore uedbet官网-uedbetapp
Since 1980
More than 30 years of unremitting efforts
Focus on
Anti tuberculosis drugs
uedbet官网-uedbetapp "no longer bothered by tuberculosis"
We should enrich first-line anti tuberculosis drugs, build second-line multi drug resistant anti tuberculosis drugs, and make efforts to benefit global TB patients based on domestic and global perspectives.
In 2019, R & D investment accounts for 7.65% of the company's sales revenue.
uedbet官网-uedbetapp has successively introduced rifampicin freeze-dried powder injection for injection and isoniazid injection, and developed a domestic class I new drug PA-824, bringing more drug choices for tuberculosis patients.
uedbet官网-uedbetapp builds a new tuberculosis drug production line according to who PQ standard
We have built a professional team for the promotion and service of anti tuberculosis drugs in China, strengthened hospital promotion and channel coverage, and improved academic promotion ability and brand building.
In 2010, uedbet官网-uedbetapp became a member of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as "Fosun Pharmaceutical", stock code: 600196. Sh, 02196. HK). With the mission of "no longer suffering from tuberculosis" and the vision of "creating an international first-class anti tuberculosis drug pharmaceutical enterprise", Hongqi Pharmaceutical Co., Ltd. enriches first-line anti tuberculosis drugs, constructs second-line multi drug resistant anti tuberculosis drugs, and is committed to benefiting global TB patients based on domestic and global perspectives.
Copyright hongqipharma.com All rights reserved Powered by:300.cn Shenyang 辽icp备12005917号-1 (辽)-非经营性-2018-0012
Add:Shenyang Hunnan New District envelope 6th Street Tel:024-23786268-8012 Fax:024-23786263